AN2 Therapeutics (ANTX) Net Cash Flow (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Net Cash Flow data on file, last reported at $33.5 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $33.5 million, up 2555.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.5 million (up 811.6% YoY), and the FY2025 annual result was -$1.4 million, down 124.72% from the prior year.
• Net Cash Flow climbed to $33.5 million in Q1 2026 per ANTX's latest filing, from $1.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $70.4 million in Q1 2022 and troughed at -$41.9 million in Q2 2022.
• A 5-year average of $2.4 million and a median of -$510000.0 in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow tumbled 973.22% in 2023, then soared 2555.78% in 2026.
• A 5-year view of Net Cash Flow shows it stood at -$1.6 million in 2022, then plunged by 973.22% to -$17.0 million in 2023, then increased by 28.56% to -$12.1 million in 2024, then jumped by 115.98% to $1.9 million in 2025, then soared by 1629.18% to $33.5 million in 2026.
• Business Quant data shows ANTX's Net Cash Flow at $33.5 million in Q1 2026, $1.9 million in Q4 2025, and -$242000.0 in Q3 2025.